All the fundraising deals in the longevity market (from Q4 2024 to Q4 2025)
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
The longevity market raised around $2.66 billion across 25 deals from Q4 2024 through Q4 2025.
Retro Biosciences led the pack with a record-breaking $1 billion Series A, while Function Health closed the year as a new unicorn with its $298 million Series B.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
Insights
- Cellular reprogramming captured half of all longevity funding, with over $1.3 billion going to companies like Retro Biosciences and NewLimit that aim to reverse cellular aging.
- Q1 2025 alone brought in $1.16 billion, but 86.5% of that came from a single deal, showing how one mega-round can reshape quarterly totals in the longevity space.
- Consumer longevity platforms raised over $550 million, proving that people are willing to pay for healthspan optimization tools before FDA-approved drugs even exist.
- Q3 2025 was the quietest quarter with just $54 million across 2 deals, likely because companies from earlier rounds were still deploying their capital.
- Big Pharma entered the longevity race: Eli Lilly invested in NewLimit and partnered with Insilico Medicine, signaling mainstream pharmaceutical interest in aging biology.
- The Middle East emerged as a serious longevity hub, with Abu Dhabi's M42 leading a $150 million investment in Juvenescence and Hevolution Foundation backing multiple deals.
- Neurodegeneration therapeutics attracted $134 million across 5 deals, as Alzheimer's and Parkinson's remain the clearest clinical proving grounds for longevity science.
- Function Health's $298 million raise and $2.5 billion valuation made it the largest consumer longevity diagnostics company, offering 160+ biomarker testing at $365 per year.
- The average longevity deal size was $106 million, but this number is heavily skewed by Retro Biosciences' billion-dollar round, which alone accounted for 37.5% of all funding.
- Nine out of ten top investors made just 2-3 deals each, suggesting the longevity investor base is still spreading out rather than concentrating around a few dominant funds.
In our longevity market deck, we will give you useful market maps and grids
Summary table of the funding deals in the longevity market (last 5 quarters)
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
You can also read our detailed analysis to understand how funding activity in the longevity market has evolved over the last few years.
Also, you should know that we have a dedicated page, updated weekly, with all the latest fundraising deals in the longevity market.
| Name | What they do | Amount ($) | Quarter | Source(s) |
|---|---|---|---|---|
| Retro Biosciences | Develops AI-powered therapies to extend human healthspan by 10 years | $1,000M | Q1 2025 | TechCrunch |
| Function Health | Offers comprehensive lab testing with 160+ biomarkers for early disease detection | $298M | Q4 2025 | TechCrunch |
| OURA | Makes smart rings that track sleep, heart rate, and activity for health optimization | $200M | Q4 2024 | PRNewswire |
| BioAge Labs | Develops therapies for metabolic diseases by targeting the biology of human aging | $198M | Q4 2024 | BioSpace |
| Minovia Therapeutics | Creates mitochondrial therapies to treat aging-related cellular decline | $180M | Q2 2025 | FierceBiotech |
| Juvenescence | Develops medicines targeting core aging mechanisms in cognition and metabolism | $150M | Q2 2025 | Longevity.Technology |
| NewLimit | Develops epigenetic reprogramming medicines to restore youthful cell function | $130M | Q2 2025 | TechCrunch |
| Insilico Medicine | Uses AI to discover drugs for fibrosis, cancer, and aging-related diseases | $110M | Q1 2025 | PRNewswire |
| Blueprint | Offers personalized longevity protocols, supplements, and AI health optimization | $60M | Q4 2025 | Longevity.Technology |
| Aeovian Pharmaceuticals | Develops mTORC1 inhibitors to restore cellular quality control in aging | $55M | Q4 2025 | BusinessWire |
| SciNeuro Pharmaceuticals | Develops therapeutics for Alzheimer's and Parkinson's disease | $53M | Q4 2025 | Longevity.Technology |
| NewLimit (Extension) | Extends Series B to accelerate liver rejuvenation clinical studies | $45M | Q4 2025 | Longevity.Technology |
| Illimis Therapeutics | Develops TAM receptor therapies for Alzheimer's and immune diseases | $42M | Q3 2025 | PRNewswire |
| Loyal | Develops FDA-approved drugs to extend the lifespan of dogs | $22M | Q1 2025 | FinSMEs |
| Shift Bioscience | Uses AI to identify genes that safely rejuvenate human cells | $16M | Q4 2024 | Labiotech |
| Booster Therapeutics | Develops medicines to clear misfolded proteins that cause neurodegeneration | $15M | Q4 2024 | Longevity.Technology |
| Grey Matter Neurosciences | Creates ultrasound devices to treat Alzheimer's and dementia non-invasively | $14M | Q1 2025 | MobiHealthNews |
| Circulate Health | Offers plasma exchange treatments to remove age-accelerating substances from blood | $12M | Q3 2025 | FinSMEs |
| Celularity Inc | Develops placenta-derived cell therapies for aging-related conditions | $12M | Q4 2025 | Longevity.Technology |
| Generation Lab | Provides biological age testing across 19 organ systems from blood tests | $11M | Q4 2025 | Longevity.Technology |
| MindImmune Therapeutics | Develops immune-focused treatments for Alzheimer's disease | $10.2M | Q4 2025 | Longevity.Technology |
| Junevity | Uses siRNA to reset aged cells and extend lifespan | $10M | Q1 2025 | DDW |
| Junevity (Extension) | Extends seed to advance lead candidate toward human clinical trials | $10M | Q4 2025 | Longevity.Technology |
| Tomorrow.Bio | Provides cryogenic preservation services for future revival and rejuvenation | $5.5M | Q2 2025 | EU-Startups |
| clock.bio | Decodes rejuvenation biology to identify genes that reverse cellular aging | $5.3M | Q4 2024 | BusinessWire |
In our longevity market deck, we identify pain points entrepreneurs should prioritize
How has funding activity in the longevity market changed over time?
Q1 2025 was by far the most active quarter with $1.16 billion raised, but this was almost entirely driven by Retro Biosciences' $1 billion mega-round, which alone made up 86.5% of the quarter's total.
Q3 2025 was the quietest period with only 2 deals totaling $54 million, likely because companies that raised earlier in the year were still deploying their capital before returning to market.
Longevity funding in Q4 2025 increased by over 900% compared to Q3 2025, jumping from $54 million to $554 million, while compared to Q4 2024, the total grew by about 28% from $434 million.
If you remove the top 1-2 mega-deals from each quarter, the longevity market shows a more steady pace of around $30-60 million per quarter from mid-sized therapeutics and diagnostics companies.
| Quarter | Number of Deals | Total Raised ($) | Comment |
|---|---|---|---|
| Q4 2024 | 5 | $434M | Strong quarter led by OURA's $200M and BioAge's $198M IPO in diagnostics and therapeutics. |
| Q1 2025 | 5 | $1,156M | Record quarter dominated by Retro Biosciences' $1B Series A, the largest longevity round ever. |
| Q2 2025 | 4 | $466M | Balanced quarter with three $100M+ deals from Minovia, Juvenescence, and NewLimit. |
| Q3 2025 | 2 | $54M | Quiet summer quarter with only Illimis ($42M) and Circulate Health ($12M) closing rounds. |
| Q4 2025 | 9 | $554M | Most deals in a single quarter, led by Function Health's $298M unicorn-minting Series B. |
| All Quarters | 25 | $2,664M | Total longevity funding across 5 quarters, with cellular reprogramming as the top category. |
In our longevity market deck, we identify repeatable patterns you can use if you’re building in this market
Which startups in the longevity market raised the largest rounds over the last months?
These startups raised the most recently in the longevity market:
- Retro Biosciences raised $1 billion because the company has three drugs in development, an OpenAI partnership for AI-powered discovery, and backing from Sam Altman who believes aging is a solvable problem.
- Function Health raised $298 million because the company reached 200,000 members, launched an AI Medical Intelligence Lab, and proved that consumers will pay for comprehensive longevity diagnostics.
- OURA raised $200 million because the smart ring maker launched Ring 4 with advanced sensors and is expanding into healthcare partnerships for clinical-grade health tracking.
- BioAge Labs raised $198 million through its IPO because the company has a clinical-stage pipeline for metabolic diseases and later announced a $550 million partnership with Novartis.
- Minovia Therapeutics raised $180 million via SPAC because the company's mitochondrial therapy approach addresses a root cause of cellular aging and rare disease treatment.
- Juvenescence raised $150 million because Abu Dhabi's M42 healthcare giant backed the company to establish a longevity drug development hub in the Middle East.
- NewLimit raised $130 million because the epigenetic reprogramming company, co-founded by Coinbase CEO Brian Armstrong, is advancing liver rejuvenation therapies toward clinical trials.
- Insilico Medicine raised $110 million because the AI drug discovery company has a clinical-stage pipeline and is validating its platform with a lead candidate for lung fibrosis.
- Blueprint raised $60 million because Bryan Johnson's longevity protocol attracted celebrity investors like Kim Kardashian and the Winklevoss brothers who want to democratize anti-aging.
- Aeovian Pharmaceuticals raised $55 million because the company is advancing mTOR-targeting drugs, a validated aging pathway, with support from Hevolution Foundation and other longevity investors.
In our longevity market deck, we answer all the common questions from investors and entrepreneurs
Is the longevity market shifting toward smaller or bigger deals?
The average longevity deal size over the past five quarters was $106 million, but this figure is heavily influenced by Retro Biosciences' billion-dollar round which represented 37.5% of all funding.
Breaking it down by quarter, the average ranged from $27 million in Q3 2025 to $231 million in Q1 2025. The wide swings reflect how a single mega-deal in cellular reprogramming or longevity diagnostics can dramatically change quarterly averages.
If you exclude the top 1-2 outliers per quarter, the typical longevity therapeutics and healthspan startup raises between $10 million and $60 million, suggesting a healthy mid-market for aging science companies.
| Quarter | Number of Deals | Average Deal Size ($) | Deals Below $2M | Deals Above $50M |
|---|---|---|---|---|
| Q4 2024 | 5 | $87M | 0 | 2 |
| Q1 2025 | 5 | $231M | 0 | 2 |
| Q2 2025 | 4 | $116M | 0 | 3 |
| Q3 2025 | 2 | $27M | 0 | 0 |
| Q4 2025 | 9 | $62M | 0 | 4 |
| All Quarters | 25 | $106M | 0 | 11 |
In our longevity market deck, we help you understand how the market is structured
How concentrated was funding activity in the longevity market?
Longevity funding was extremely concentrated in most quarters, with the top 3 deals typically capturing over 95% of quarterly totals. In Q1 2025, Retro Biosciences alone accounted for 86.5% of all funding, showing how one cellular reprogramming mega-round can dominate the entire longevity sector.
Q4 2025 showed the most balanced distribution, with the top deal (Function Health) representing 53.8% and the top 3 capturing 73.3%, suggesting the longevity diagnostics and therapeutics market is gradually maturing beyond single-company dependence.
| Quarter | Number of Deals | % by Top 1 | % by Top 3 | % by Top 10 |
|---|---|---|---|---|
| Q4 2024 | 5 | 46.1% | 96.8% | 100% |
| Q1 2025 | 5 | 86.5% | 98.3% | 100% |
| Q2 2025 | 4 | 38.7% | 98.8% | 100% |
| Q3 2025 | 2 | 77.8% | 100% | 100% |
| Q4 2025 | 9 | 53.8% | 73.3% | 100% |
| All Quarters | 25 | 37.5% | 56.3% | 89.2% |
In our longevity market deck, we have designed useful charts to give you full market clarity
Which categories in the longevity market received the most funding?
Therapeutics focused on cellular reprogramming raised $1.33 billion (50% of all funding) across 6 deals. This concentration reflects investor belief that epigenetic reprogramming offers the most promising path to actual rejuvenation, with companies like Retro Biosciences and NewLimit leading the way.
Diagnostics and consumer health platforms raised $509 million (19% of total) across 3 deals. Function Health, OURA, and Generation Lab proved that consumers are ready to pay for longevity monitoring tools, even before FDA-approved anti-aging drugs exist.
Neurodegeneration therapeutics raised $134 million (5% of total) across 5 deals. Alzheimer's and Parkinson's remain the key clinical proving grounds for aging science, with companies like SciNeuro and Illimis targeting novel mechanisms beyond traditional amyloid approaches.
| Category Name | Number of Deals | Total Raised ($) | Startups and Amount |
|---|---|---|---|
| Therapeutics / Cellular Reprogramming | 6 | $1,331M | Retro Biosciences ($1,000M), NewLimit ($175M), Junevity ($20M), Shift Bioscience ($16M) |
| Diagnostics / Consumer Health | 3 | $509M | Function Health ($298M), OURA ($200M), Generation Lab ($11M) |
| Therapeutics / Neurodegeneration | 5 | $134M | SciNeuro ($53M), Illimis ($42M), Booster Therapeutics ($15M), Grey Matter ($14M), MindImmune ($10.2M) |
In our longevity market deck, we cover the latest tech updates shaping the market
Who are the biggest investors in the longevity market?
Khosla Ventures is the most active longevity investor with 3 deals, backing NewLimit, Loyal, and Circulate Health. The firm has consistently bet on companies targeting validated aging pathways, from epigenetic reprogramming to plasma exchange therapies.
Apollo Health Ventures participated in 2 deals, investing in Booster Therapeutics and Aeovian Pharmaceuticals. Apollo focuses specifically on aging biology, backing companies that target proteasome function and mTOR pathways.
Valor Equity Partners backed 2 longevity companies, investing in both Loyal (dog lifespan extension) and NewLimit (human epigenetic reprogramming). Valor has positioned itself across both animal and human longevity therapeutics.
Eli Lilly made 2 strategic investments in the longevity space, backing NewLimit's extension round and partnering with Insilico Medicine. The pharmaceutical giant's involvement signals mainstream pharma interest in aging as a drug development category.
Goldcrest Capital and Godfrey Capital co-led both of Junevity's raises, investing a combined $20 million across two rounds. These investors have shown strong conviction in siRNA-based cellular reprogramming approaches.
Andreessen Horowitz (a16z) participated in at least 2 longevity deals including Function Health's $298 million round. The firm has been expanding its bio portfolio into consumer-facing longevity diagnostics.
Disclaimer: this investor list may be incomplete; we focus on publicly disclosed lead and prominent recurring investors, so some frequent minority participants may be underrepresented. "Total funded" does not represent the amount personally invested by an individual investor. Instead, it refers to the aggregate amount raised across all fundraising rounds in which the investor participated.
| Investor | Number of Deals | Total Funded ($) | Startups |
|---|---|---|---|
| Khosla Ventures | 3 | $164M | NewLimit, Loyal, Circulate Health |
| Apollo Health Ventures | 2 | $70M | Booster Therapeutics, Aeovian Pharmaceuticals |
| Valor Equity Partners | 2 | $152M | Loyal, NewLimit |
| Eli Lilly | 2 | $155M | NewLimit (Extension), Insilico Medicine |
| Goldcrest Capital | 2 | $20M | Junevity (Q1), Junevity (Q4) |
| Godfrey Capital | 2 | $20M | Junevity (Q1), Junevity (Q4) |
| a16z | 2 | $298M+ | Function Health, other investments |
| Hevolution Foundation | 2 | $55M+ | Aeovian Pharmaceuticals, grant investments |
In our longevity market deck, we track adoption trends and shifts in consumer behavior
Related blog posts
- What is the latest update in the longevity market?
- What are the latest news in the longevity market?
- What is the real market size of the longevity market?
- What are the latest funding news in the longevity market?
- What are the fundraising trends in the longevity market?
- All the funding deals for the longevity market
- Which startups have raised the most funding in the longevity market?
- What are the most valued startups in the longevity market?
